Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going
A Russo, T Franchina, GRR Ricciardi… - Critical reviews in …, 2017 - Elsevier
The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
[HTML][HTML] Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino… - … England Journal of …, 2017 - Mass Medical Soc
Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component
JCH Yang, MJ Ahn, DW Kim… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …
[HTML][HTML] Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease …
K Haratani, H Hayashi, T Tanaka, H Kaneda… - Annals of oncology, 2017 - Elsevier
Background The efficacy of programmed death-1 blockade in epidermal growth factor
receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with …
receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with …
[HTML][HTML] Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer
S Jenkins, JCH Yang, SS Ramalingam, K Yu… - Journal of Thoracic …, 2017 - Elsevier
Introduction Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive,
costly, and not always feasible for patients with late-stage disease. The clinical utility of the …
costly, and not always feasible for patients with late-stage disease. The clinical utility of the …
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
W Wang, Z Song, Y Zhang - Cancer medicine, 2017 - Wiley Online Library
A sensitive and convenient method for detecting epidermal growth factor receptor (EGFR)
T790M mutations from circulating tumor DNA (ct DNA) in advanced non–small cell lung …
T790M mutations from circulating tumor DNA (ct DNA) in advanced non–small cell lung …
[HTML][HTML] A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R
EE Ke, Q Zhou, QY Zhang, J Su, ZH Chen… - Journal of Thoracic …, 2017 - Elsevier
Introduction Increasing evidence has demonstrated that exon 19 deletions (Del19) and
L858R mutation in EGFR have different prognostic and predictive roles in NSCLC. We …
L858R mutation in EGFR have different prognostic and predictive roles in NSCLC. We …
[HTML][HTML] Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
SK Liang, MS Hsieh, MR Lee, LT Keng, JC Ko… - Oncotarget, 2017 - ncbi.nlm.nih.gov
We evaluated the real-world efficacy and side effects of afatinib as a first-line therapy for
advanced EGFR mutation-positive lung adenocarcinoma. The medical records of patients …
advanced EGFR mutation-positive lung adenocarcinoma. The medical records of patients …
Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
Y Liu, L Sun, ZC Xiong, X Sun, SL Zhang… - OncoTargets and …, 2017 - Taylor & Francis
Purpose The purpose of this meta-analysis was to explore the influences of pretreatment de
novo and posttreatment-acquired epidermal growth factor receptor (EGFR) T790M mutations …
novo and posttreatment-acquired epidermal growth factor receptor (EGFR) T790M mutations …